Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398594 | 1.00 | MAPT (0.37) | MAPTNPSR1MEN1KMT2ACYP4F2 | |
| SCHEMBL9017773 | 0.88 | NPSR1 (0.37) | MAPTNPSR1MEN1KMT2ACYP4F2 | |
| SCHEMBL11757280 | 0.84 | APLNR (0.31) | APLNR | |
| SCHEMBL19447708 | 0.82 | MAPT (0.34) | MAPTNPSR1CYP4F2CYP4A11TSHR | |
| SCHEMBL28354361 | 0.80 | MAPT (0.36) | MAPTNPSR1MEN1KMT2ACYP4F2 | |
| SCHEMBL4644937 | 0.80 | APLNR (0.38) | NPSR1MEN1KMT2AALDH1A1APLNR | |
| SCHEMBL15219234 | 0.80 | APLNR (0.38) | NPSR1MEN1KMT2AALDH1A1APLNR | |
| SCHEMBL29184375 | 0.78 | NPSR1 (0.40) | MAPTNPSR1CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL29618225 | 0.77 | MAPT (0.37) | MAPTNPSR1MEN1KMT2ACYP4F2 | |
| SCHEMBL16865201 | 0.77 | MAPT (0.35) | MAPTNPSR1MEN1KMT2ACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-3329918-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1673085-A4 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| CN-1252049-A | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives | PHARMACEUTICA & UPJOHN S P A (IT) | 2000-05-03 | — | — | CN | disclosed |
| EP-0973720-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998040344-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MAPT 4161/4885NPSR1 3253/4885MEN1 1228/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MAPT 4161/4885NPSR1 3253/4885MEN1 1228/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MAPT 4161/4885NPSR1 3253/4885MEN1 1228/4885 |
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | NR0B1, NR2C2, ERBB2 | MAPT 4675/4885NPSR1 424/4885MEN1 4326/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MAPT 4118/4885NPSR1 3268/4885MEN1 1333/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | MAPT 4878/4885NPSR1 4157/4885MEN1 304/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MAPT 4118/4885NPSR1 3268/4885MEN1 1333/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MAPT 4161/4885NPSR1 3253/4885MEN1 1228/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | MAPT 4108/4885NPSR1 3359/4885MEN1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.